EPIX Pharmaceuticals (NASDAQ: EPIX) 34% HIGHER; announced compelling top-line results from a Phase 2a two-week clinical trial of its novel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE